Dear SIRS, the concept of "alarmins" makes a lot of sense!

Intensive Care Medicine

Volumn 34, Issue 2, 2008, Pages 218-221

  Pugin, Jérôme ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN; LIPOPOLYSACCHARIDE; PROTEIN S 100; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

BACTERIAL INFECTION; CRITICALLY ILL PATIENT; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG EFFECT; EDITORIAL; ENDOTOXEMIA; FEVER; HUMAN; INTENSIVE CARE UNIT; LEUKOCYTOSIS; LUNG INJURY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TISSUE INJURY;

DEFENSINS; HUMANS; INTENSIVE CARE UNITS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 38849164800     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-007-0888-4     Document Type: Editorial

References (46)

1. Bone RC (1991) Let's agree on terminology: definitions of sepsis. Crit Care Med 19:973-976
2. Bone RC (1992) Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome). JAMA 268:3452-3455
3. Brun-Buisson C (2000) The epidemiology of the systemic inflammatory response. Intensive Care Med [Suppl] 26(1):S64-S74
4. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP (1995) The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273:117-123
5. Bone RC, Sibbald WJ, Sprung CL (1992) The ACCP-SCCM Consensus Conference on Sepsis and Organ Failure. Chest 101:1481-1483
6. Marshall J (1997) Both the disposition and the means of cure: "Severe SIRS," "sterile shock," and the ongoing challenge of description. Crit Care Med 25:1765-1766
7. Moore FA, Moore EE (1995) Evolving concepts in the pathogenesis of postinjury multiple organ failure. Surg Clin North Am 75:257-277
8. Opal SM (1998) The uncertain value of the definition for SIRS. Systemic inflammatory response syndrome. Chest 113:1442-1443
9. Vincent JL (1997) Dear SIRS, I'm sorry to say that I don't like you. Crit Care Med 25:372-374
10. Dugernier TL, Laterre PF, Wittebole X, Roeseler J, Latinne D, Reynaert MS, Pugin J (2003) Compartmentalization of the inflammatory response during acute pancreatitis: correlation with local and systemic complications. Am J Respir Crit Care Med 168:148-157
11. Pugin J, Ricou B, Steinberg KP, Suter PM, Martin TR (1996) Proinflammatory activity in bronchoalveolar lavage fluids from patients with ARDS, a prominent role for interleukin-1. Am J Respir Crit Care Med 153:1850-1856
12. Pugin J, Verghese G, Widmer MC, Matthay MA (1999) The alveolar space is the site of intense inflammatory and profibrotic reactions in the early phase of acute respiratory distress syndrome. Crit Care Med 27:304-312
13. Goldie AS, Fearon KC, Ross JA, Barclay GR, Jackson RE, Grant IS, Ramsay G, Blyth AS, Howie JC (1995) Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group. JAMA 274:172-177
14. Fumeaux T, Pugin J (2002) Role of interleukin-10 in the intracellular sequestration of human leukocyte antigen-DR in monocytes during septic shock. Am J Respir Crit Care Med 166:1475-1482
15. Munford RS, Pugin J (2001) Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 163:316-321
16. Singer M (2007) System interactions. Novartis Found Symp 280:252-262
17. Pugin J (2007) Immunostimulation is a rational therapeutic strategy in sepsis. Novartis Found Symp 280:21-27
18. Janeway CA Jr (1992) The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 13:11-16
19. Matzinger P (1994) Tolerance, danger, and the extended family. Annu Rev Immunol 12:991-1045
20. Matzinger P (2002) The danger model: a renewed sense of self. Science 296:301-305
21. Matzinger P (2002) An innate sense of danger. Ann N Y Acad Sci 961:341-342
22. Fraser CK, Diener KR, Brown MP, Hayball JD (2007) Improving vaccines by incorporating immunological coadjuvants. Expert Rev Vaccines 6:559-578
23. Adib-Conquy M, Cavaillon JM (2007) Stress molecules in sepsis and systemic inflammatory response syndrome. FEBS Lett 581:3723-3733
24. Bianchi ME (2007) DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81:1-5
25. Oppenheim JJ, Yang D (2005) Alarmins: chemotactic activators of immune responses. Curr Opin Immunol 17:359-365
26. Harris HE, Raucci A (2006) Alarmin (g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep 7:774-778
27. Raucci A, Palumbo R, Bianchi ME (2007) HMGB1: a signal of necrosis. Autoimmunity 40:285-289
28. El Mezayen R, El Gazzar M, Seeds MC, McCall CE, Dreskin SC, Nicolls MR (2007) Endogenous signals released from necrotic cells augment inflammatory responses to bacterial endotoxin. Immunol Lett 111:36-44
29. Miyake K (2007) Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 19:3-10
30. Yang H, Wang H, Tracey KJ (2001) HMG-1 rediscovered as a cytokine. Shock 15:247-253
31. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ, Yang H (2006) HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26:174-179
32. Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B, Nawroth P, Andersson U, Harris RA, Harris HE (2005) RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 61:1-9
33. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248-251
34. Mantell LL, Parrish WR, Ulloa L (2006) Hmgb-1 as a therapeutic target for infectious and inflammatory disorders. Shock 25:4-11
35. Gibot S, Massin F, Cravoisy A, Barraud D, Nace L, Levy B, Bollaert PE (2007) High-mobility group box 1 protein plasma concentrations during septic shock. Intensive Care Med 33:1347-1353
36. Levy RM, Mollen KP, Prince JM, Kaczorowski DJ, Vallabhaneni R, Liu S, Tracey KJ, Lotze MT, Hackam DJ, Fink MP, Vodovotz Y, Billiar TR (2007) Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol (epub ahead of print 25 July)
37. Sawa H, Ueda T, Takeyama Y, Yasuda T, Shinzeki M, Nakajima T, Kuroda Y (2006) Blockade of high mobility group box-1 protein attenuates experimental severe acute pancreatitis. World J Gastroenterol 12:7666-7670
38. Yang R, Harada T, Mollen KP, Prince JM, Levy RM, Englert JA, Gallowitsch-Puerta M, Yang L, Yang H, Tracey KJ, Harbrecht BG, Billiar TR, Fink MP (2006) Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol Med 12:105-114
39. Esmon CT (2004) Interactions between the innate immune and blood coagulation systems. Trends Immunol 25:536-542
40. Hagiwara S, Iwasaka H, Matsumoto S, Noguchi T (2007) High dose antithrombin III inhibits HMGB1 and improves endotoxin-induced acute lung injury in rats. Intensive Care Med DOI 10.007/s00134-007-0887-5
41. Wiedermann C J, Romisch J (2002) The anti-inflammatory actions of antithrombin-a review. Acta Med Austriaca 29:89-92
42. Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, Keinecke HO, Warren BL, Opal SM (2006) Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 4:90-97
43. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286:1869-1878
44. Ito T, Kawahara K, Nakamura T, Yamada S, Nakamura T, Abeyama K, Hashiguchi T, Maruyama I (2007) High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. J Thromb Haemost 5:109-116
45. Wang H, Li W, Goldstein R, Tracey KJ, Sama AE (2007) HMGB1 as a potential therapeutic target. Novartis Found Symp 280:73-85
46. Izuishi K, Tsung A, Jeyabalan G, Critchlow ND, Li J, Tracey KJ, Demarco RA, Lotze MT, Fink MP, Geller DA, Billiar TR (2006) Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J Immunol 176:7154-7158